{rfName}
Pa

Indexed in

License and use

Altmetrics

Analysis of institutional authors

Villanueva, RAuthorGil MAuthor
Share
Publications
>
Review

Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication

Publicated to:Therapeutic Advances In Medical Oncology. 11 (UNSP 1758835919833867): 1758835919833867- - 2019-05-01 11(UNSP 1758835919833867), DOI: 10.1177/1758835919833867

Authors: Bellet, M; Ahmad, F; Villanueva, R; Valdivia, C; Palomino-Doza, J; Ruiz, A; Gonzàlez, X; Adrover, E; Azaro, A; Valls-Margarit, M; Parra, JL; Aguilar, J; Vidal, M; Martin, A; Gavilá, J; Escrivá-de-Romaní, S; Perelló, A; Hernando, C; Lahuerta, A; Zamora, P; Reyes, V; Alcalde, M; Masanas, H; Céliz, P; Ruíz, I; Gil, M; Seguí, MA; de la Peña, L

Affiliations

Complejo Hosp Univ Albacete, Serv Oncol Med, Albacete, Spain - Author
Ctr Invest Biomed Red Canc, Valencia, Spain - Author
Fdn Inst Valenciano Oncol, Valencia, Spain - Author
Fdn Onkol, Donostia San Sebastian, Spain - Author
Health Services Research in Cancer. Idibell - Author
Hosp Clin Univ Valencia, Incl Inst Invest Sanitaria, Valencia, Spain - Author
Hosp del Mar, Inst Neuropsiquiatria & Addict, Barcelona, Spain - Author
Hosp del Mar, Med Res Inst, Barcelona, Spain - Author
Hosp Gen Cataluna, SOLTI, Inst Oncol Dr Rosell, Barcelona, Spain - Author
Hosp Moises Broggi, Inst Catala Oncol, Barcelona, Spain - Author
Hosp Univ 12 Octubre, Hereditary Cardiopathies Unit, Madrid, Spain - Author
Hosp Univ La Paz, Serv Oncol Med, Madrid, Spain - Author
Hosp Univ Son Espases, Palma De Mallorca, Spain - Author
Hosp Univ, Parc Tauli Sabadell, Barcelona, Spain - Author
IDIBELL Inst Invest Biomed Bellvitge, Inst Catala Oncol, Barcelona, Spain - Author
Inst Invest Biomed August Pi & Sunyer, Hosp Clin Barcelona, Barcelona, Spain - Author
Inst Invest Biomed August Pi & Sunyer, Translat Genom & Targeted Therapeut Solid Tumors, Barcelona, Spain - Author
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL). Institut d'Investigació Biomèdica de Bellvitge - Author
SOLTI, Barcelona, Spain - Author
Vall dHebron Inst Oncol, Passeig Vall dHebron 119-129, Barcelona, Spain - Author
Vall dHebron Univ Hosp, Infect Dis Dept, Barcelona, Spain - Author
Vall dHebron Univ Hosp, Med Oncol Dept, Barcelona, Spain - Author
Vall dHebron Univ Hosp, Passeig Vall dHebron 119-129, Barcelona, Spain - Author
Vall dHebron Univ Hosp, Radiat Oncol Dept, Barcelona, Spain - Author
Vall dHebron Univ Hosp, Unitat Cures Palliat, Barcelona, Spain - Author
Vall dHebron Univ Hosp, Vall dHebron Res Inst, Barcelona, Spain - Author
See more

Abstract

Keywords
5 (2 bromovinyl) 2' deoxyuridineAbdominal painAciclovirAlanine aminotransferaseAlopeciaAnemiaAntacid agentAntidepressant agentArea under the curveAspartate aminotransferaseAstheniaBilirubinBlood brain barrierBreast cancerBreast cancer resistance proteinCancer hormone therapyCancer resistanceCdk inhibitorsCitalopramClinical practiceCytochrome p450Cytochrome p450 3a inhibitorDrug distributionDrug dose reductionDrug efficacyDrug interactionDrug metabolismDrug safetyDrug toxicityDrug withdrawalDysgeusiaEfavirenzElectrocardiographyEpiphoraEscitalopramFamciclovirFatigueFollow upGanciclovirGastrointestinal refluxHumanInfectionLetrozoleLiver functionLiver function testLiver toxicityMagnesium hydroxideMaintenance therapyMedication therapy managementMetastatic breast cancerMirtazapineNausea and vomitingNeutropeniaNonnucleoside reverse transcriptase inhibitorNucleoside analogOseltamivirPalbociclibPhase 1 clinical trial (topic)Phase 2 clinical trial (topic)PlaceboPrevalencePriority journalProteinase inhibitorPruritusPsychotropic agentQt prolongationQtc intervalQuality of lifeQuestionnaireRabeprazoleRashReviewRibociclibRisk assessmentRisk factorRna directed dna polymerase inhibitorStomatitisThrombocytopeniaUnindexed drugValganciclovirWorkshop

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Therapeutic Advances In Medical Oncology due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2019, it was in position 34/244, thus managing to position itself as a Q1 (Primer Cuartil), in the category Oncology.

From a relative perspective, and based on the normalized impact indicator calculated from World Citations provided by WoS (ESI, Clarivate), it yields a value for the citation normalization relative to the expected citation rate of: 1.3. This indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 14, 2024)

This information is reinforced by other indicators of the same type, which, although dynamic over time and dependent on the set of average global citations at the time of their calculation, consistently position the work at some point among the top 50% most cited in its field:

  • Weighted Average of Normalized Impact by the Scopus agency: 1.47 (source consulted: FECYT Feb 2024)
  • Field Citation Ratio (FCR) from Dimensions: 8.61 (source consulted: Dimensions May 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-05-15, the following number of citations:

  • WoS: 37
  • Scopus: 41
  • Europe PMC: 17
  • OpenCitations: 42
Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-05-15:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 89.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 89 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 20.2.
  • The number of mentions on the social network X (formerly Twitter): 22 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.